North America Endothelial Dysfunction Market Forecast to 2028
North America Endothelial Dysfunction Market Forecast to 2028 – Regional Analysis – by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.
According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.
North America Endothelial Dysfunction Market Overview
The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.
North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
North America Endothelial Dysfunction Market Segmentation
The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.
Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet’s disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.
Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.
Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.
ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America endothelial dysfunction market was valued at US$ 951.83 million in 2022 and is expected to reach US$ 1,247.30 million by 2028, registering a CAGR of 4.6% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes and obesity are the critical factors attributed to the North America endothelial dysfunction market expansion.
Endothelial dysfunction is a strong prognostic factor for cardiovascular events and mortality in the population. Assessment of endothelial function can aid in selecting therapies and assessing their response. While invasive angiography remains the gold standard for measuring coronary endothelial function, several noninvasive imaging techniques have evolved to study both coronary and peripheral endothelial function. Available endothelial testing methods are helpful for mechanistically understanding diseases and risk stratification and prognoses, such as high-resolution B-mode ultrasound and Doppler, computed tomography angiography, cardiovascular magnetic resonance (CMR), magnetic resonance imaging (MRI), and positron emission tomography (PET). Noninvasive methods for assessing endothelial function are mainly used in scientific research since there is a significant risk of complications due to the specificity of endovascular interventions. One of the noninvasive methods to assess endothelial function is to measure fluorescence. Flow-mediated skin fluorescence (FMSF) is based on the fluorescence measurement of the reduced nicotinamide adenine dinucleotide (NADH) emitted by skin cells in response to UV light excitation. The test consists of three phases: recording the fluorescence’s background intensity, occlusion phase, and reaction registration.
On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of North America endothelial dysfunction market.
Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet’s disease, and others. The hypertension segment held 33.1% share of North America endothelial dysfunction market in 2022, amassing US$ 315.17 million. It is projected to garner US$ 424.42 million by 2028 to expand at 5.1% CAGR during 2022-2028.
Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 73.9% share of North America endothelial dysfunction market in 2022, amassing US$ 703.86 million. It is projected to garner US$ 908.51 million by 2028 to expand at 4.4% CAGR during 2022-2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held 51.8% share of North America endothelial dysfunction market in 2022, amassing US$ 493.93 million. It is projected to garner US$ 659.34 million by 2028 to expand at 5.0% CAGR during 2022-2028.
Based on country, the North America endothelial dysfunction market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 80.5% share of North America endothelial dysfunction market in 2022. It was assessed at US$ 766.34 million in 2022 and is likely to hit US$ 1,011.96 million by 2028, exhibiting a CAGR of 4.7% during 2022-2028.
Key players operating in the North America endothelial dysfunction are ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH, among others.
In April 2023, Perimed has signed an agreement with Lovell Government Services. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the United States. With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf. In April 2021, Berkeley Lab has developed flow-mediated dilation device to monitor both endothelial function and endothelium-independent vasodilation.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America endothelial dysfunction market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America endothelial dysfunction market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the endothelial dysfunction market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 North America Endothelial Dysfunction Market – by Cause
1.3.2 North America Endothelial Dysfunction Market – by Test Type
1.3.3 North America Endothelial Dysfunction Market – by End User
1.3.4 North America Endothelial Dysfunction Market – by Country
2. North America Endothelial Dysfunction Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Endothelial Dysfunction Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Expert Opinion
5. North America Endothelial Dysfunction Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Incidences of Cardiovascular Diseases
5.1.2 Rising Incidences of High Cholesterol, Diabetes And Obesity
5.2 Market Restraints
5.2.1 Disadvantages Associated with the Techniques for Screening of Endothelial Dysfunction
5.3 Market Opportunities
5.3.1 Rising Usage of Novel Biomarkers and Therapeutic Strategies
5.4 Future Trends
5.4.1 Use of Noninvasive Methods to Assess Endothelial Dysfunction
5.5 Impact Analysis
6. Endothelial Dysfunction Market – North America Analysis
6.1 North America Endothelial Dysfunction Market Revenue Forecast and Analysis
7. North America Endothelial Dysfunction Market Analysis – by Cause
7.1 Overview
7.2 North America Endothelial Dysfunction Market, By Cause, 2022 & 2028 (%)
7.3 Hypertension
7.3.1 Overview
7.3.2 Hypertension: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.5 Hypercholestrolaemia
7.5.1 Overview
7.5.2 Hypercholestrolaemia: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.6 Behcet’s Disease
7.6.1 Overview
7.6.2 Behcet’s Disease: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.7 Obesity
7.7.1 Overview
7.7.2 Obesity: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8. North America Endothelial Dysfunction Market Analysis – by Test Type
8.1 Overview
8.2 North America Endothelial Dysfunction Market, By Test Type, 2022 & 2028 (%)
8.3 Invasive Tests
8.3.1 Overview
8.3.2 Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4 Non-Invasive Tests
8.4.1 Overview
8.4.2 Non-Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.3 Flow Mediated Dilatory
8.4.3.1 Overview
8.4.3.2 Flow Mediated Dilatory: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.4 Venous Occlusion Plethysmography
8.4.4.1 Overview
8.4.4.2 Venous Occlusion Plethysmography: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.5 Peripheral Arterial Tonometry (PAT)
8.4.5.1 Overview
8.4.5.2 Peripheral Arterial Tonometry (PAT): North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.6 Circulating Markers
8.4.6.1 Overview
8.4.6.2 Circulating Markers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.7 Others
8.4.7.1 Overview
8.4.7.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9. North America Endothelial Dysfunction Market Analysis – by End User
9.1 Overview
9.2 North America Endothelial Dysfunction Market, By End User, 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostics Centers
9.4.1 Overview
9.4.2 Diagnostics Centers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.5 Clinics
9.5.1 Overview
9.5.2 Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
10. North America Endothelial Dysfunction Market – Revenue and Forecast to 2028 – Country Analysis
10.1 North America: Endothelial Dysfunction Market
10.1.1 Overview
10.1.1.1 US: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 US: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.1.4 US: Endothelial Dysfunction Market, by Test Type – 2020-2028 (US$ Million)
10.1.1.1.4.1 US: Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 US: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.2 Canada: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Canada: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.2.4 Canada: Endothelial Dysfunction Market, by Test Type – 2020-2028 (US$ Million)
10.1.1.2.4.1 Canada: Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 Canada: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.3 Mexico: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Endothelial Dysfunction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Mexico: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.3.4 Mexico: Endothelial Dysfunction Market, by Test Type – 2020-2028 (US$ Million)
10.1.1.3.4.1 Mexico: Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 Mexico: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
11. North America Endothelial Dysfunction Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Endothelial Dysfunction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 ZOLL Medical Corp
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Lawrence Berkeley National Laboratory
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Endothelix Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Perimed AB
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6
12.4.7 Key Developments
12.5 SMART Medical Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Everist Health Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medizinische Messtechnik GmbH
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About Research Team
13.2 Glossary of Terms
LIST OF TABLES
Table 2. Novel Soluble and Cell Component Biomarkers of Endothelia Dysfunction in Cardiovascular Diseases
Table 3. US Endothelial Dysfunction Market, by Cause – Revenue and Forecast to 2028 (US$ Million)
Table 4. US Endothelial Dysfunction Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Endothelial Dysfunction Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Endothelial Dysfunction Market, by Cause – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Endothelial Dysfunction Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Endothelial Dysfunction Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 11. Mexico Endothelial Dysfunction Market, by Cause – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico Endothelial Dysfunction Market, by Test Type – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Endothelial Dysfunction Market, by Non-Invasive Tests – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Endothelial Dysfunction Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 15. Recent Inorganic Growth Strategies in the Endothelial Dysfunction Market
Table 16. Recent Organic Growth Strategies in the Endothelial Dysfunction Market
Table 17. Glossary of Terms, Endothelial dysfunction market
LIST OF FIGURES
Figure 2. North America Endothelial Dysfunction Market, by Country
Figure 3. North America Endothelial Dysfunction Market Overview
Figure 4. Hypertension Account for Largest Share of Cause Segment in North America Endothelial Dysfunction Market
Figure 5. The US Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Expert Opinion
Figure 8. North America Endothelial Dysfunction Market: Impact Analysis of Drivers and Restraints
Figure 9. North America Endothelial Dysfunction Market – Revenue Forecast and Analysis – 2020-2028
Figure 10. North America Endothelial Dysfunction Market, by Cause, 2022 & 2028 (%)
Figure 11. Hypertension: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. Hypercholestrolaemia: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. Behcet’s disease: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 15. Obesity: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 17. North America Endothelial Dysfunction Market, by Test Type, 2022 & 2028 (%)
Figure 18. Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 19. Non-Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 20. Flow Mediated Dilatory: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 21. Venous Occlusion Plethysmography: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 22. Peripheral Arterial Tonometry (PAT): North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 23. Circulating Markers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 24. Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. North America Endothelial Dysfunction Market, by End User, 2022 & 2028 (%)
Figure 26. Hospitals and Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. Diagnostics Centers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 29. Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. North America: Endothelial Dysfunction Market, by Key Country – Revenue (2022) (US$ Million)
Figure 31. North America: Endothelial Dysfunction Market, by Country, 2022 & 2028 (%)
Figure 32. US: Endothelial Dysfunction Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Canada: Endothelial Dysfunction Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Mexico: Endothelial Dysfunction Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Growth Strategies in the Endothelial Dysfunction Market
The List of Companies – North America Endothelial Dysfunction Market
o Endothelix Inc
o Everist Health Inc
o Lawrence Berkeley National Laboratory
o Medizinische Messtechnik GmbH
o Perimed AB
o SMART Medical Ltd
o ZOLL Medical Corp
You must be logged in to post a review.
Reviews
There are no reviews yet.